Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2022, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, February 23, 2022, during which management will discuss the fourth quarter and full year 2021 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

Vanda Pharmaceuticals Inc  VNDA shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis.  Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Why Are Vanda Pharma Shares Plunging Today?

WASHINGTON, Feb. 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the efficacy and safety of tradipitant in treating the symptoms of gastroparesis. The study did not meet its prespecified primary endpoint which was the difference between drug and placebo on the change of the severity of nausea from baseline at week 12 of treatment.

Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis

WASHINGTON, Jan. 14, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) with MSN Pharmaceuticals Inc., MSN Laboratories Private Limited (together MSN) and Impax Laboratories LLC (Impax) to resolve Vanda's patent litigation against MSN regarding MSN's Abbreviated New Drug Application seeking approval of its generic version of Vanda's HETLIOZ® (tasimelteon). Under the License Agreement, Vanda granted MSN and Impax a non-exclusive license to manufacture and commercialize MSN's version of HETLIOZ® in the U.S. effective March 13, 2035, unless prior to that date Vanda obtains pediatric exclusivity for HETLIOZ®, in which case, the license will be effective July 27, 2035.

Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN

Amid the 2021 Biotech Bear market, there are many fundamentally strong companies trading at a deep discount to their true worth. As a growth/value play, Vanda Pharmaceuticals is a promising investment with substantial upsides.

Vanda: A Prudent Business With Upsides

WASHINGTON, Nov. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda management will participate at the following upcoming investor conferences in November 2021: The Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021. A corporate presentation is scheduled for 10:00 a.m.

Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q3 2021 Results - Earnings Call Transcript

Vanda (VNDA) delivered earnings and revenue surprises of -30.00% and -4.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Misses Q3 Earnings and Revenue Estimates

Vanda Pharmaceuticals (NASDAQ:VNDA) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Vanda Pharmaceuticals: Q3 Earnings Insights

WASHINGTON, Nov. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2021. "Vanda is approaching another pivotal moment in its 18-year history with the upcoming completion of the Phase III study of tradipitant in gastroparesis and anticipated results by the end of this year.

Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results

Vanda Pharmaceuticals (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.

Vanda Pharmaceuticals Earnings Preview

WASHINGTON, Oct. 27, 2021 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2021 on Wednesday, November 3, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 3, 2021, during which management will discuss the third quarter 2021 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Q3 Release

WASHINGTON, Oct. 14, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI's Catalyst Day on Monday, October 18, 2021. Mihael H. Polymeropoulos, M.D.

Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day

Vanda (VNDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vanda (VNDA) Upgraded to Buy: Here's Why

WASHINGTON, Sept. 7, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021.

Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference

Vanda (VNDA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Vanda (VNDA) Loses 21.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

WASHINGTON, Aug. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients. Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified primary endpoint.

Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients

Vanda (VNDA) Upgraded to Buy: What Does It Mean for the Stock?

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2021 Results - Earnings Call Transcript

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and -4.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Matches Q2 Earnings Estimates

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 6.25% year over year to $0.17, which beat the estimate of $0.14.

Vanda Pharmaceuticals: Q2 Earnings Insights

WASHINGTON, July 28, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2021. "Vanda had another outstanding quarter of commercial revenue growth as we resumed activity across a number of our clinical programs.

Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results

WASHINGTON, July 21, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2021 on Wednesday, July 28, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, July 28, 2021, during which management will discuss the second quarter 2021 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce Second Quarter 2021 Financial Results on July 28, 2021

Vanda (VNDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

News for Vanda Pharmaceuticals Stock (VNDA)